Table 3

Prevalence data (%) based on HUNT3 questionnaires (Q1 or Q2) and general practitioner diagnoses (GPD)
Women age groups Men age groups
20-39 40-59 60-79 80 + 20-39 40-59 60-79 80 +
Heart burn
Q2: A lot of heart burn 6.1 7.9 6.3 6.2 4.9 6.3 8.6 7.9
GPD: Heart burn or reflux (D03/D84) 3.9 8.2 10.0 11.0 2.5 7.6 12.1 12.0
Cardiovascular diseases
Q1: Angina pectoris 0.3 1.5 9.6 21.4 0.2 0.7 4.4 15.5
GPD: Angina pectoris (K74) 0.1 2.2 13.9 26.4 0 0.8 6.8 21.1
Q1: Myocardial infarction 0.1 2.3 10.1 21.2 0.0 0.5 3.0 8.6
GPD: Myocardial infarction (K75or K76) 1.0 3.3 12.9 18.8 0.5 1.3 4.7 10.4
Q1: Cerebral insult 0.6 1.5 5.4 11.6 0.3 1.1 3.9 8.6
GPD: Cerebral insult (K90 + 91) 0.4 2.2 7.3 17.0 0.4 1.4 5.7 14.2
Q1: Arterial hypertension 1.2 14.7 38.1 44.1 2.1 12.7 36.9 49.8
GPD: Arterial hypertension (K86 or K87) 2.7 14.7 37.4 42.2 2.2 12.9 37.1 49.4
NorPD: Drugs arterial hyper-tension (C02-03, 07–09) 1.7 16.0 51.5 70.3 2.2 15.7 49.5 67.7
Inflammatory and musculoskeletal diseases
Q1: Spondylarthritis or
rheumatoid arthritis 1.5 4.1 5.3 6.0 1.9 4.7 7.2 8.8
GPD: Spondylarthritis or rheumatoid arthritis (L88) 1.5 3.4 4.5 5.6 1.5 4.7 7.9 8.7
Q1: Arthrosis 0.8 6.1 17.2 23.3 1.0 12.8 34.2 45.5
GPD: Arthrosis hip or knee (L 89 + 90 + 91) 1.7 7.5 21.5 29.8 1.7 10.2 33.6 43.4
Q1: Osteoporosis 0.1 0.3 1.2 3.1 0.3 1.9 11.1 20.6
GPD: Osteoporosis L95 0.2 0.6 1.5 2.9 0.2 1.4 10.8 22.7
Neurological diseases
Q1: Headache 37.0 34.3 18.7 10.7 56.9 47.7 26.8 16.6
GPD: Headache (N01) 10.8 9.9 7.9 6.1 18.6 16.5 12.6 11.0
Q1: Migraine 3.1 4.5 2.7 3.4 10.4 11.2 5.1 5.0
GPD: Migraine (N89) 3.8 4.4 2.6 1.5 9.5 11.6 7.1 2.4
NorPD: Use of migraine drugs (N02) 1.0 1.0 0.5 0.2 3.5 4.9 2.0 0.3
Q1: Epilepsy 1.5 1.2 1.2 1.9 1.3 1.4 0.7 1.4
GPD: Epilepsy (N88) 1.8 1.7 1.8 1.5 1.5 1.7 1.5 1.2
Mental diseases and insomnia
Q2: HADS anxiety score 
    >
 8#
11.9 11.7 7.2 8.2 18.4 17.4 15.6 13.2
GPD: Anxiety or feeling of anxiety (P 01 + 74 +79) 6.7 8.5 8.5 8.6 9.7 14.1 14.0 15.4
Q2: HADS depression score 
    >
 8#
6.4 9.4 11.7 18.8 6.2 8.3 9.8 16.3
GPD: Depression or feeling of depression (P 03 + 76) 11.0 18.1 16.0 11.1 19.6 31.3 28.0 21.7
Q2: Insomnia many evenings or mornings a week 11.6 13.8 16.2 15.4 13.1 21.3 25.8 25.3
GPD: Sleeping disorder (P06) 6.3 8.6 18.8 24.0 6.3 13.3 21.7 32.4
Q1: COPD or chronic bronch 1.0 2.0 5.6 5.4 1.5 2.7 4.6 4.2
GPD: COPD or chronic bronchitis (R95) 0.1 1.9 7.9 13.2 0.2 1.8 7.2 7.0
Q1: Asthma 10.5 9.3 9.4 7.2 12.4 9.4 10.4 8.6
GPD: Asthma (R96) 10.6 7.0 9.2 10.0 10.4 9.7 11.9 9.9
Q1: Use of asthma or copd drugs in the last 5 years 8.1 7.5 11.3 9.6 10.4 9.6 12.5 9.7
GP prescription asthma drugs in the last 5 year (R03) 7.4 8.7 15.1 17.4 9.8 11.4 17.3 12.6
NorPD: Use of asthma drugs in 2008 (R03) 4.6 5.6 11.6 14.2 5.7 7.7 13.0 9.1
Skin diseases
Q1: Psoriasis 4.1 6.8 7.0 3.8 3.3 6.2 6.6 4.1
GPD: Psoriasis (S91) 2.0 4.6 5.5 4.6 2.7 4.5 5.8 2.8
Endocrine disorders
Q1: Hyperthyreosis 0.3 0.7 1.3 2.5 1.4 2.6 3.4 3.2
GPD: Hyperthyreosis (T85) 0.2 0.5 0.7 0.7 0.6 1.9 2.0 2.0
Q1: Hypothyreosis 0.6 2.1 2.9 5.3 4.1 8.0 12.3 12.1
GPD: Hypothyreosis (T86) 1.4 1.9 4.2 6.7 3.2 7.8 12.7 13.8
GP prescription thyroid hormone (H03AA01) 0.5 1.5 3.3 5.1 2.2 7.0 12.1 12.5
NorPD: Use of thyroid hormone (H03AA01) 0.5 2.0 3.7 5.9 2.6 7.9 14.2 13.4
Q1: Diabetes mellitus 0.8 3.4 9.2 9.2 0.8 2.4 6.9 9.7
GPD: Diabetes mellitus (T89 + 90) 1.2 4.8 13.7 16.3 1.4 3.6 10.4 13.0
GP prescription antidiabetic drug (A10A or A10B) 0.8 4.0 10.9 10.9 1.2 2.8 7.9 8.8
NorPD: Antidiabetic drug (A10A or A10B) 1.1 4.1 11.1 11.7 1.5 2.6 8.4 9.2
Urinary tract
Q2: Urinary incontinence 4.7 7.6 10.4 13.1 22.2 27.5 27.4 32.8
GPD: Urinary incontinence (U04) 1.0 0.5 3.0 8.7 2.2 6.8 10.5 22.0

HUNT data are restricted to the municipalities being represented by eight randomly selected general practices, and include 28 872 HUNT3 participants (57% of invited in these municipalities). Data from Norwegian Prescription Registry (NorPD) include the entire county for the year 2008.

# Hospital Anxiety and Depression Scale (HADS) 14 items, cut-off 8 indicate minor, moderate and severe disease (REF).

In parenthesis: For diagnosis – codes according to the International Classification of Primary Care (ICPC2), for medication codes according to The Anatomical Therapeutic Chemical Classification System (ATC).

Langhammer et al.

Langhammer et al. BMC Medical Research Methodology 2012 12:143   doi:10.1186/1471-2288-12-143

Open Data